Evidence map›Paper›PMID 31387230›Full record

ReviewMarine drugs2019

Possibilities of Fucoidan Utilization in the Development of Pharmaceutical Dosage Forms.

Aleksandra Citkowska, Marta Szekalska, Katarzyna Winnicka

Open access · goldAbstract readReview
In one paragraph

Review in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
18.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 216 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Genotoxicity evaluation of fucoidan-richToxicological research · 2025
    Article
  18. Fucoidan fromFrontiers in pharmacology · 2025
    Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Aleksandra CitkowskaDepartment of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15-222 Białystok, Poland.
Marta SzekalskaDepartment of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15-222 Białystok, Poland.ORCID 0000-0003-4340-5350
Katarzyna WinnickaDepartment of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15-222 Białystok, Poland. kwin@umb.edu.pl.ORCID 0000-0002-1013-610X
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fucoidan is a polysaccharide built from L-fucose molecules. The main source of this polysaccharide is the extracellular matrix of brown seaweed (

Indexed as

AnimalsBiocompatible MaterialsChemistry, PharmaceuticalPhaeophyceaePolysaccharidesSea CucumbersSea UrchinsSeaweedTechnology, PharmaceuticalBiocompatible MaterialsfucoidanPolysaccharidesfucoidanfucospheresmarine-derivedmultifunctional polymerpharmaceutical formulationspolysaccharide

Identifiers

PMID31387230
PMCPMC6722496
OpenAlexW2964822268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.